Nidan Laboratories & Healthcare Ltd (NIDAN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003561,
    "name": "Nidan Laborator.",
    "stock_name": "Nidan Laborator.",
    "full_name": "Nidan Laboratories & Healthcare Ltd",
    "name_url": "stocks-analysis/nidan-laborator",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "18.95",
    "chg": 0.3,
    "chgp": "1.61%",
    "dir": 1,
    "prev_price": "18.65",
    "mcapval": "26.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "NIDAN",
    "ind_name": "Hospital",
    "ind_code": 94,
    "indexname": "",
    "isin": "INE0J6L01013",
    "curr_date": "Dec 26",
    "curr_time": "",
    "bse_nse_vol": 10000,
    "exc_status": "Active",
    "traded_date": "Dec 26, 2025",
    "traded_date_str": "2025 12 26",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nidan-laborator-1003561-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Nidan Laboratories & Healthcare Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nidan-laboratories-healthcare-ltd-is-rated-strong-sell-3770823",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NidanLaboratori_mojoScore_3770823.png",
        "date": "2025-12-26 15:13:38",
        "description": "Nidan Laboratories & Healthcare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Nidan Laborator. Evaluation Revised Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/nidan-laborator-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3750525",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NidanLaborator_mojoScore_3750525.png",
        "date": "2025-12-08 10:10:51",
        "description": "Nidan Laborator., a microcap player in the hospital sector, has undergone a revision in its market assessment reflecting shifts in its fundamental and technical outlook. This update highlights nuanced changes across quality, valuation, financial trends, and technical indicators, providing investors with a clearer understanding of the stock’s current positioning within a challenging market environment."
      },
      {
        "title": "Nidan Laboratories & Healthcare: Valuation Metrics Reflect Shift in Market Assessment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nidan-laboratories-healthcare-valuation-shifts-signal-changing-market-sentiment-3737472",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NidanLaboratori_valuationdot_3737472.png",
        "date": "2025-12-01 08:02:25",
        "description": "Nidan Laboratories & Healthcare has experienced a notable revision in its valuation parameters, with key metrics such as the price-to-earnings (P/E) ratio and price-to-book value (P/BV) indicating a shift from previously attractive levels to a more moderate assessment. This article examines these changes in the context of the hospital sector and peer comparisons, providing insight into the stock’s current market positioning."
      },
      {
        "title": "Nidan Laboratories & Healthcare Hits Upper Circuit Amid Strong Buying Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nidan-laboratories-healthcare-hits-upper-circuit-amid-strong-buying-pressure-3735490",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NidanLaboratori_stocks_hitting_upper_circuit_3735490.png",
        "date": "2025-11-28 11:00:11",
        "description": "Nidan Laboratories & Healthcare Ltd witnessed a significant surge in its share price on 28 Nov 2025, hitting the upper circuit limit of 13.68% and closing at ₹21.60. This sharp movement reflects robust buying interest and a notable outperformance relative to its sector and broader market indices."
      },
      {
        "title": "Nidan Laboratories & Healthcare Surges with Unprecedented Buying Interest, Hits Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nidan-laboratories-healthcare-surges-1974-on-unprecedented-buying-interest-amid-upper-circuit-lock-3735405",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NidanLaboratori_only_buyers_3735405.png",
        "date": "2025-11-28 10:20:41",
        "description": "Nidan Laboratories & Healthcare Ltd has witnessed extraordinary buying momentum, registering a remarkable 19.74% gain in a single trading session. The stock has hit the upper circuit with only buy orders in the queue, signalling intense demand and a potential multi-day circuit scenario as sellers remain absent from the market."
      },
      {
        "title": "How has been the historical performance of Nidan Laborator.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-nidan-laborator-3694313",
        "imagepath": "",
        "date": "2025-11-12 23:34:03",
        "description": "Answer:\nThe historical performance of Nidan Laborator shows fluctuations in key financial metrics over the years, with a notable recovery in the latest fiscal year.\n\nBreakdown:\nNidan Laborator's net sales for the year ending March 2025 were reported at 24.53 Cr, a slight increase from 24.18 Cr in March 2024, following a dip from 29.66 Cr in March 2022. The total operating income mirrored this trend, reaching 24.53 Cr in March 2025. The company's total expenditure, excluding depreciation, increased to 19.46 Cr in March 2025 from 17.73 Cr in March 2024. Operating profit (PBDIT) decreased to 7.32 Cr in March 2025 from 9.20 Cr in the previous year, while profit before tax rebounded to 2.76 Cr from a loss of 2.37 Cr in March 2024. Consequently, profit after tax also improved to 1.98 Cr from a loss of 3.23 Cr. The earnings per share (EPS) showed a positive turnaround, reaching 1.42 in March 2025 after being negat..."
      },
      {
        "title": "Is Nidan Laborator. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nidan-laborator-overvalued-or-undervalued-3687842",
        "imagepath": "",
        "date": "2025-11-11 08:14:39",
        "description": "As of 10 November 2025, the valuation grade for Nidan Laborator. has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 14.25, an EV to EBITDA of 7.38, and a Price to Book Value of 0.41, all of which suggest that the stock is trading at a discount compared to its intrinsic value.\n\nIn comparison with its peers, Nidan Laborator. stands out with a significantly lower PE ratio than Max Healthcare, which is at 88.71, and also offers a more favorable EV to EBITDA ratio compared to Apollo Hospitals at 28.24. Despite recent underperformance relative to the Sensex, with a year-to-date return of -29.64% against the Sensex's 8.16%, the attractive valuation metrics suggest that Nidan Laborator. may present a compelling investment opportunity moving forward...."
      },
      {
        "title": "Is Nidan Laborator. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nidan-laborator-overvalued-or-undervalued-3684266",
        "imagepath": "",
        "date": "2025-11-10 08:14:49",
        "description": "As of 7 November 2025, the valuation grade for Nidan Laborator. has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 14.67, an EV to EBITDA of 7.55, and a Price to Book Value of 0.43. These ratios suggest that while the company is not undervalued, it also does not appear to be significantly overvalued compared to its peers.\n\nIn comparison to its industry peers, Nidan Laborator. has a lower PE ratio than Apollo Hospitals, which stands at 65.65, and a more favorable EV to EBITDA ratio compared to Max Healthcare at 56.83. However, the company's return metrics, such as a ROCE of 3.44% and ROE of 2.90%, highlight its struggles in generating returns relative to its equity. Additionally, Nidan Laborator. has underperformed against the Sensex over the past year, with a stock return of -34.69% compared to the Sensex's 5.34%, reinforc..."
      },
      {
        "title": "Nidan Laboratories Adjusts Valuation Grade Amidst Competitive Market Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nidan-laboratories-healthcares-valuation-grade-downgraded-from-attractive-to-fair-3684398",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NidanLaboratori_valuationdot_3684398.png",
        "date": "2025-11-10 08:02:31",
        "description": "Nidan Laboratories & Healthcare has adjusted its valuation, with a P/E ratio of 14.67 and a low price-to-book value of 0.43. Key metrics include an enterprise value to EBITDA ratio of 7.55 and a ROCE of 3.44%. The company maintains a modest valuation compared to peers amid market challenges."
      }
    ],
    "total": 89,
    "sid": "1003561",
    "stock_news_url": "https://www.marketsmojo.com/news/nidan-laboratories-healthcare-1003561"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Nidan Laboratories & Healthcare Ltd is Rated Strong Sell

2025-12-26 15:13:38

Nidan Laboratories & Healthcare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 22 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Nidan Laborator. Evaluation Revised Amid Mixed Financial and Technical Signals

2025-12-08 10:10:51

Nidan Laborator., a microcap player in the hospital sector, has undergone a revision in its market assessment reflecting shifts in its fundamental and technical outlook. This update highlights nuanced changes across quality, valuation, financial trends, and technical indicators, providing investors with a clearer understanding of the stock’s current positioning within a challenging market environment.

Nidan Laboratories & Healthcare: Valuation Metrics Reflect Shift in Market Assessment

2025-12-01 08:02:25

Nidan Laboratories & Healthcare has experienced a notable revision in its valuation parameters, with key metrics such as the price-to-earnings (P/E) ratio and price-to-book value (P/BV) indicating a shift from previously attractive levels to a more moderate assessment. This article examines these changes in the context of the hospital sector and peer comparisons, providing insight into the stock’s current market positioning.

Nidan Laboratories & Healthcare Hits Upper Circuit Amid Strong Buying Pressure

2025-11-28 11:00:11

Nidan Laboratories & Healthcare Ltd witnessed a significant surge in its share price on 28 Nov 2025, hitting the upper circuit limit of 13.68% and closing at ₹21.60. This sharp movement reflects robust buying interest and a notable outperformance relative to its sector and broader market indices.

Nidan Laboratories & Healthcare Surges with Unprecedented Buying Interest, Hits Upper Circuit

2025-11-28 10:20:41

Nidan Laboratories & Healthcare Ltd has witnessed extraordinary buying momentum, registering a remarkable 19.74% gain in a single trading session. The stock has hit the upper circuit with only buy orders in the queue, signalling intense demand and a potential multi-day circuit scenario as sellers remain absent from the market.

How has been the historical performance of Nidan Laborator.?

2025-11-12 23:34:03

Answer: The historical performance of Nidan Laborator shows fluctuations in key financial metrics over the years, with a notable recovery in the latest fiscal year. Breakdown: Nidan Laborator's net sales for the year ending March 2025 were reported at 24.53 Cr, a slight increase from 24.18 Cr in March 2024, following a dip from 29.66 Cr in March 2022. The total operating income mirrored this trend, reaching 24.53 Cr in March 2025. The company's total expenditure, excluding depreciation, increased to 19.46 Cr in March 2025 from 17.73 Cr in March 2024. Operating profit (PBDIT) decreased to 7.32 Cr in March 2025 from 9.20 Cr in the previous year, while profit before tax rebounded to 2.76 Cr from a loss of 2.37 Cr in March 2024. Consequently, profit after tax also improved to 1.98 Cr from a loss of 3.23 Cr. The earnings per share (EPS) showed a positive turnaround, reaching 1.42 in March 2025 after being negat...

Is Nidan Laborator. overvalued or undervalued?

2025-11-11 08:14:39

As of 10 November 2025, the valuation grade for Nidan Laborator. has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued. Key ratios include a PE Ratio of 14.25, an EV to EBITDA of 7.38, and a Price to Book Value of 0.41, all of which suggest that the stock is trading at a discount compared to its intrinsic value. In comparison with its peers, Nidan Laborator. stands out with a significantly lower PE ratio than Max Healthcare, which is at 88.71, and also offers a more favorable EV to EBITDA ratio compared to Apollo Hospitals at 28.24. Despite recent underperformance relative to the Sensex, with a year-to-date return of -29.64% against the Sensex's 8.16%, the attractive valuation metrics suggest that Nidan Laborator. may present a compelling investment opportunity moving forward....

Is Nidan Laborator. overvalued or undervalued?

2025-11-10 08:14:49

As of 7 November 2025, the valuation grade for Nidan Laborator. has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 14.67, an EV to EBITDA of 7.55, and a Price to Book Value of 0.43. These ratios suggest that while the company is not undervalued, it also does not appear to be significantly overvalued compared to its peers. In comparison to its industry peers, Nidan Laborator. has a lower PE ratio than Apollo Hospitals, which stands at 65.65, and a more favorable EV to EBITDA ratio compared to Max Healthcare at 56.83. However, the company's return metrics, such as a ROCE of 3.44% and ROE of 2.90%, highlight its struggles in generating returns relative to its equity. Additionally, Nidan Laborator. has underperformed against the Sensex over the past year, with a stock return of -34.69% compared to the Sensex's 5.34%, reinforc...

Nidan Laboratories Adjusts Valuation Grade Amidst Competitive Market Landscape

2025-11-10 08:02:31

Nidan Laboratories & Healthcare has adjusted its valuation, with a P/E ratio of 14.67 and a low price-to-book value of 0.43. Key metrics include an enterprise value to EBITDA ratio of 7.55 and a ROCE of 3.44%. The company maintains a modest valuation compared to peers amid market challenges.

View All News